Original Musical If/Then Dazzles Audiences Across the Country
February 9, 2016
Get the details on the inspiration behind this new, ambitious production
If/Then is a contemporary new musical starring Elizabeth, a city planner who moves back to New York to restart her life. But when her carefully designed plans collide with the whims of fate, Elizabeth’s life splits into two parallel paths. If/Then follows both stories simultaneously as this modern woman faces the intersection of choice and chance.
The Balancing Act’s correspondent, Amber Milt, takes viewers to New York City where she will hear firsthand from the creative team as they talk about the inspiration behind this new, ambitious production and the process of building an original musical. We’ll hear from the Pulitzer Prize and Tony Award-winning team of Tom Kitt (Music) and Brian Yorkey (Book and Lyrics), along with one of the show’s producers Patrick Catullo.
In addition to the creative team, viewers will go behind the scenes of rehearsals for the upcoming national tour where they’ll meet and hear from original Broadway cast members Tony Award winners LaChanze, Anthony Rapp and James Snyder. We’ll also hear from audience members who talk about what the show means to them and how we can all relate to the themes within this thought-provoking musical.
Catch all the action on The Balancing Act, Tuesday, May 31 and June 7, 2016 at 7:30 a.m. (ET/PT). To purchase tickets to If/Then, learn more about where the show is headed next, and for even more exclusive content, go to www.BroadwayBalancesAmerica.com.
Bringing the best tips from the experts in Atlanta in business, beauty, wealth management, child healthcare, car shopping, and more. Each year, Atlanta’s Women’s Entrepreneurship Initiative selects 15 local female entrepreneurs for a 15-month business training program. We meet women who have grown their companies, created jobs, and broke through the glass ceiling. With some […]
iMCD is the deadliest subtype of Castleman disease. Approximately one third of patients die within five years of diagnosis, and another third die within 10 years if not treated.
There are no effective treatment options for people with unresectable or metastatic chondrosarcoma despite many attempts by multiple pharmaceutical companies over the past few decades.